BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the launch of the BD Neopak™ 2.25 mL prefillable glass syringe, specifically designed for biopharmaceutical manufacturers that develop, manufacture and market high-value and sensitive biologic drugs that require higher quality levels and performance to treat chronic diseases such as, rheumatoid arthritis, psoriasis, lupus and severe asthma.
“Through our continued investment in innovation, this new syringe enables biopharmaceutical manufacturers to develop drug-syringe combination products with extended injection intervals. This will provide patients with more time between injections and decrease the frequency of injections,” said Peter Nolan, worldwide president of Pharmaceutical Systems for BD. “By offering higher volume subcutaneous injections, the BD Neopak 2.25 mL prefillable glass syringe is designed to help reduce the number of necessary injections, aiming to improve the safety and convenience for patients.”
Built on the legacy of BD’s most advanced biotech syringe platform, the BD Neopak 2.25 mL glass prefillable syringe is designed to reduce undesired interactions, such as drug degradation or aggregation between the primary container and drug, to support biopharmaceutical manufacturers’ efforts to mitigate product development and commercialization risks. The new syringe is now commercially available in the United States, Europe and Japan.
BD is a leading partner for biopharmaceutical manufacturers offering a wide range of services to assess drug-container compatibility, evaluate system-related functional requirements, human factors and provide regulatory expertise to support drug development. The BD Neopak 2.25 mL glass prefillable syringe expands the BD Neopak™ portfolio, which also includes a BD Neopak™ 1 mL glass prefillable syringe.
BD (bd.com) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
Contact: Monique N. Dolecki - BD Investor Relations
P: 201 847 5378 - E: monique_dolecki[.]bd.com.